Browse the failure-mode index

1 real negative results, null findings, and replication failures in Diseases of the digestive system. Gastroenterology · Replication Failure. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Replication FailureOpen accessDiseases of the digestive system. Gastroenterology

Ten-day vonoprazan–amoxicillin dual therapy versus 14-day esomeprazole–amoxicillin dual therapy for first-line eradication: a prospective multicenter randomized controlled trial

Ben-Gang Zhou, Ming-Wen Guo, Li-Juan Zhang et al. · 2024 · Therapeutic Advances in Gastroenterology

Background: The efficacy of the 14-day esomeprazole–amoxicillin (EA) dual therapy in eradicating Helicobacter pylori ( H. pylori ) has been widely discussed previously. Vonoprazan, a novel potassium-competitive acid blocker, presents rapid, potent, and long-lasting acid inhibitory effects compared to esomeprazole. However, there is currently a scarcity of direct comparisons between the 10-day vonoprazan–amoxicillin (VA) and the 14-day EA dual therapy for H. pylori eradication. Objectives: This study aimed to compare the efficacy and safety of the 10-day VA and the 14-day EA dual therapy for H.

View details →